Mersana Therapeutics Inc. is expected to announce on Tuesday a $334 million deal with Teva Pharmaceuticals Industries Ltd. for XMT-1107, a preclinical revival of the old antiangiogenic drug fumagillin. (BioWorld Today)

Tengion Inc., which priced a $30 million initial public offering on Friday, was easily the earliest-stage biotech to try its luck in the current IPO window. (BioWorld Today)

CorMedix Inc. caught much of the biotech industry by surprise late Thursday when the relatively obscure cardio-renal specialty pharma firm priced a $12.5 million initial public offering on AMEX. (BioWorld Today)